Charlie Fazio, MD, senior vice president and medical director of HealthPartners discusses how to balance different payment models in order to understand their impacts on cost and patient outcomes when they are implemented.
Charlie Fazio, MD, senior vice president and medical director of HealthPartners, discusses how to balance different payment models in order to understand their impacts on cost and patient outcomes when they are implemented.
Transcript
There are a lot of different delivery and payment models being tested and implemented—how do you balance multiple at once and still understand the impact they are having on cost and outcomes?
As we are doing these payment trials we certainly worry about overlap and confounding the results as we try them. Fortunately, most of the things we are trying don’t have a lot of overlaps.
So, you think about bundles for orthopedic care—those are pretty well isolated and can be assessed one against the other, and in the ideal world we are looking at some patient outcomes, some patient satisfaction, and then the efficiency of the process. Those would be pretty well separated from an oncology bundle that we might be working on.
Then, an awful lot of the implementation trials we’re doing are in payments for primary care. Even if we look at population-based payments for those, and how those are working, and how patient satisfaction goes with those, the specialty bundles contribute to that but don’t necessarily confuse it.
So, we are carful to separate them, where it’s not always perfect, but they’re isolated enough that we can get a pretty good sense for how they’re working.
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More